NPI: 1598875460 · TUPELO, MS 38801 · General Acute Care Hospital · NPI assigned 08/30/2006
Authorized official TOPPIN, BRUCE controls 20+ related entities in our dataset. Read more
| Authorized Official | TOPPIN, BRUCE (CORPORATE SECRETARY) |
| Parent Organization | NORTH MISSISSIPPI MEDICAL CENTER, INC |
| NPI Enumeration Date | 08/30/2006 |
Other providers sharing the same authorized official: TOPPIN, BRUCE
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 424,758 | $19.13M |
| 2019 | 414,972 | $19.65M |
| 2020 | 340,293 | $15.22M |
| 2021 | 349,379 | $16.02M |
| 2022 | 390,236 | $16.52M |
| 2023 | 413,590 | $17.88M |
| 2024 | 384,212 | $13.24M |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 99284 | Emergency department visit for the evaluation and management, high severity | 92,272 | 75,088 | $17.45M |
| 99285 | Emergency department visit for the evaluation and management, high severity with immediate threat to life | 36,561 | 30,141 | $9.08M |
| G0378 | Hospital observation service, per hour | 11,954 | 10,171 | $5.49M |
| J2357 | Injection, omalizumab, 5 mg | 3,728 | 2,138 | $5.43M |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 78,807 | 14,398 | $4.72M |
| 99283 | Emergency department visit for the evaluation and management, moderate severity | 32,237 | 27,052 | $4.37M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 39,412 | 30,997 | $4.17M |
| J9271 | Injection, pembrolizumab, 1 mg | 937 | 629 | $3.77M |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 49,226 | 12,481 | $2.45M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 22,630 | 15,912 | $2.25M |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 15,050 | 9,087 | $2.24M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 11,108 | 9,632 | $1.69M |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 42,349 | 28,863 | $1.69M |
| J0897 | Injection, denosumab, 1 mg | 2,890 | 2,629 | $1.54M |
| J2323 | Injection, natalizumab, 1 mg | 539 | 477 | $1.51M |
| 96361 | Intravenous infusion, hydration; each additional hour | 30,295 | 22,584 | $1.45M |
| 71045 | Radiologic examination, chest; single view | 36,759 | 31,061 | $1.42M |
| 96375 | Therapeutic injection; each additional sequential IV push | 42,385 | 30,331 | $1.21M |
| 93458 | 1,278 | 1,158 | $1.15M | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 12,976 | 8,321 | $1.15M |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 9,785 | 7,908 | $1.12M |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 4,593 | 4,119 | $1.10M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 82,557 | 69,051 | $1.02M |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 8,437 | 3,991 | $962K |
| 47562 | 391 | 343 | $943K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | 2,293 | 2,116 | $857K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 41,957 | 33,382 | $856K |
| 87428 | 15,344 | 13,394 | $853K | |
| 80053 | Comprehensive metabolic panel | 117,402 | 90,672 | $814K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 22,598 | 6,612 | $757K |
| 70450 | Computed tomography, head or brain; without contrast material | 14,693 | 12,772 | $748K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | 5,638 | 4,929 | $718K |
| 95811 | 2,047 | 1,903 | $713K | |
| 59025 | Fetal non-stress test | 6,994 | 4,705 | $712K |
| J9299 | Injection, nivolumab, 1 mg | 233 | 130 | $699K |
| 71046 | Radiologic examination, chest; 2 views | 18,368 | 16,232 | $672K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 137,977 | 103,133 | $647K |
| 64493 | 1,708 | 1,491 | $641K | |
| 78815 | Positron emission tomography (PET) for limited area imaging | 1,334 | 1,194 | $528K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 4,331 | 3,748 | $486K |
| J1726 | Injection, hydroxyprogesterone caproate, (makena), 10 mg | 1,211 | 302 | $469K |
| 62323 | 2,311 | 2,138 | $465K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 5,014 | 4,226 | $420K |
| 99213 | Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 13,660 | 10,390 | $418K |
| 76819 | Fetal biophysical profile; without non-stress testing | 6,098 | 3,959 | $410K |
| 76820 | 5,326 | 3,551 | $404K | |
| 86885 | 6,282 | 5,126 | $397K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 8,425 | 4,665 | $393K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | 5,357 | 4,554 | $387K |
| J1439 | Injection, ferric carboxymaltose, 1 mg | 1,017 | 606 | $371K |
| 92526 | 7,330 | 2,026 | $362K | |
| 77386 | 1,926 | 159 | $359K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | 2,254 | 1,992 | $352K |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | 231 | 198 | $337K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 3,344 | 3,001 | $326K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 11,248 | 9,798 | $325K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 25,115 | 21,587 | $325K |
| 36902 | 324 | 276 | $324K | |
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 325 | 282 | $313K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 7,090 | 6,075 | $297K |
| 93304 | 840 | 784 | $295K | |
| 86900 | 6,683 | 5,394 | $291K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | 3,875 | 2,966 | $290K |
| 36430 | 2,994 | 2,110 | $286K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 21,760 | 10,105 | $283K |
| 84443 | Thyroid stimulating hormone (TSH) | 21,134 | 18,343 | $265K |
| 88307 | 1,642 | 1,338 | $259K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | 3,137 | 2,825 | $255K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 3,240 | 2,735 | $243K |
| 74019 | 4,264 | 3,732 | $243K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | 4,146 | 3,726 | $243K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 2,214 | 1,863 | $241K |
| 67028 | Intravitreal injection of a pharmacologic agent | 2,809 | 2,495 | $241K |
| G0379 | Direct admission of patient for hospital observation care | 1,844 | 1,629 | $237K |
| 76821 | 3,224 | 2,032 | $234K | |
| J0475 | Injection, baclofen, 10 mg | 676 | 646 | $231K |
| 97597 | 4,099 | 2,253 | $229K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 3,584 | 3,249 | $225K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 7,243 | 6,024 | $224K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 7,557 | 6,658 | $208K |
| 77336 | 3,422 | 1,398 | $207K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 7,415 | 6,545 | $205K |
| 99214 | Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 3,780 | 2,752 | $204K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 9,813 | 8,849 | $203K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 4,076 | 3,379 | $201K |
| 72125 | Computed tomography, cervical spine; without contrast material | 4,483 | 3,843 | $190K |
| 96415 | 4,311 | 3,039 | $189K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | 2,547 | 1,957 | $189K |
| 96367 | 5,594 | 3,260 | $184K | |
| 83880 | 8,987 | 7,720 | $184K | |
| 84484 | 27,903 | 19,549 | $184K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 2,318 | 2,165 | $177K |
| 72100 | 3,735 | 3,318 | $172K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | 28,053 | 23,359 | $172K |
| 88342 | 2,704 | 2,213 | $170K | |
| J0585 | Injection, onabotulinumtoxina, 1 unit | 863 | 674 | $167K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | 1,685 | 1,503 | $167K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | 3,101 | 669 | $158K |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | 1,921 | 1,173 | $157K |
| 92523 | 1,297 | 1,142 | $156K | |
| 87081 | 29,462 | 22,475 | $155K | |
| 77334 | 870 | 596 | $154K | |
| 87536 | 3,275 | 2,939 | $154K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | 1,089 | 949 | $152K |
| 77412 | 2,301 | 209 | $151K | |
| 88304 | 3,776 | 3,293 | $143K | |
| J0178 | Injection, aflibercept, 1 mg | 628 | 540 | $141K |
| 76801 | 1,948 | 1,613 | $141K | |
| 96401 | 4,166 | 2,702 | $140K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | 1,651 | 1,513 | $138K |
| J3262 | Injection, tocilizumab, 1 mg | 205 | 111 | $137K |
| J2469 | Injection, palonosetron hcl, 25 mcg | 3,166 | 1,613 | $136K |
| 86923 | 2,834 | 1,718 | $135K | |
| 74018 | 3,016 | 2,648 | $132K | |
| 86901 | 8,859 | 7,183 | $131K | |
| 20610 | 1,756 | 1,494 | $123K | |
| 97161 | 3,349 | 2,911 | $122K | |
| 87807 | 10,179 | 8,957 | $117K | |
| 80061 | Lipid panel | 11,541 | 10,369 | $117K |
| 80048 | Basic metabolic panel (calcium, ionized) | 19,539 | 15,922 | $115K |
| 75625 | 93 | 84 | $114K | |
| 93308 | 618 | 579 | $110K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | 1,541 | 1,291 | $108K |
| 73030 | 3,260 | 2,794 | $107K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | 1,322 | 973 | $106K |
| 82731 | 2,139 | 1,775 | $104K | |
| 36415 | Collection of venous blood by venipuncture | 51,791 | 36,816 | $103K |
| 72170 | 2,497 | 2,159 | $99K | |
| 81001 | 43,654 | 35,543 | $97K | |
| 93971 | 2,328 | 2,079 | $97K | |
| 83690 | 21,433 | 17,467 | $96K | |
| 72141 | 1,078 | 978 | $96K | |
| 73562 | 2,561 | 2,279 | $92K | |
| 86003 | 2,112 | 1,669 | $91K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 5,064 | 3,908 | $89K |
| 85027 | 20,743 | 17,153 | $87K | |
| 81025 | 13,419 | 11,234 | $86K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 13,628 | 10,125 | $85K |
| 71250 | 2,231 | 2,032 | $82K | |
| 87186 | 12,375 | 10,507 | $82K | |
| 77300 | 623 | 537 | $82K | |
| 87077 | 12,865 | 10,772 | $81K | |
| 76642 | 2,350 | 2,166 | $80K | |
| 77066 | Tomosynthesis, mammo | 1,363 | 1,284 | $79K |
| 83874 | 10,013 | 8,477 | $79K | |
| 97162 | 1,996 | 1,742 | $76K | |
| 99215 | Prolong outpt/office vis | 1,064 | 850 | $73K |
| 96417 | 2,717 | 1,520 | $72K | |
| 15275 | 123 | 48 | $72K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | 365 | 326 | $72K |
| 86360 | 2,852 | 2,599 | $71K | |
| 10060 | 679 | 597 | $71K | |
| 73630 | 1,994 | 1,784 | $70K | |
| 82553 | 10,125 | 8,314 | $70K | |
| 80305 | 15,223 | 13,291 | $69K | |
| 93923 | 1,698 | 1,575 | $69K | |
| J2505 | Injection, pegfilgrastim, 6 mg | 32 | 25 | $64K |
| 83655 | 6,321 | 5,329 | $64K | |
| 82728 | 8,423 | 7,402 | $63K | |
| 86355 | 2,857 | 2,606 | $61K | |
| 72040 | 1,794 | 1,562 | $61K | |
| 87040 | 9,312 | 5,500 | $61K | |
| 72072 | 1,285 | 1,140 | $61K | |
| 84702 | 5,330 | 3,710 | $60K | |
| 12001 | 621 | 558 | $60K | |
| 82607 | 6,431 | 5,813 | $60K | |
| 77065 | Tomosynthesis, mammo | 1,582 | 1,410 | $60K |
| 73130 | 1,737 | 1,540 | $59K | |
| 73560 | 1,868 | 1,620 | $59K | |
| 73610 | 1,455 | 1,298 | $59K | |
| 86357 | 2,852 | 2,599 | $59K | |
| 77301 | 127 | 111 | $59K | |
| 94010 | 5,987 | 5,536 | $58K | |
| 86359 | 2,852 | 2,600 | $58K | |
| 73502 | 2,086 | 1,787 | $57K | |
| 70486 | 1,125 | 970 | $57K | |
| 36600 | 1,827 | 1,575 | $57K | |
| 78227 | 200 | 188 | $55K | |
| 74230 | 820 | 738 | $55K | |
| 76770 | 973 | 877 | $54K | |
| P9040 | Red blood cells, leukocytes reduced, irradiated, each unit | 630 | 442 | $54K |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | 1,381 | 785 | $53K |
| 76830 | Ultrasound, transvaginal | 712 | 636 | $53K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 2,480 | 2,174 | $53K |
| 73590 | 1,485 | 1,261 | $52K | |
| Q5103 | Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg | 176 | 145 | $52K |
| 84703 | 9,083 | 7,685 | $51K | |
| 83735 | 13,235 | 9,976 | $51K | |
| J9312 | Injection, rituximab, 10 mg | 17 | 12 | $49K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 2,526 | 1,030 | $49K |
| J2182 | Injection, mepolizumab, 1 mg | 29 | 27 | $49K |
| 95812 | 222 | 196 | $48K | |
| 93312 | 384 | 363 | $46K | |
| 93880 | 862 | 805 | $44K | |
| 36591 | 9,159 | 5,349 | $43K | |
| 12011 | 460 | 387 | $43K | |
| 70496 | 540 | 480 | $43K | |
| 97165 | 1,250 | 1,073 | $42K | |
| 73090 | 1,074 | 871 | $42K | |
| 36561 | 43 | 38 | $42K | |
| 86480 | 1,293 | 1,162 | $41K | |
| Q5107 | Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg | 50 | 25 | $41K |
| G0127 | Trimming of dystrophic nails, any number | 4,167 | 4,017 | $40K |
| 86738 | 3,640 | 3,175 | $40K | |
| 75716 | 57 | 54 | $40K | |
| 49083 | 188 | 85 | $40K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | 603 | 541 | $39K |
| 86140 | 13,922 | 11,955 | $38K | |
| 64483 | 120 | 101 | $38K | |
| 95990 | 605 | 570 | $37K | |
| 97116 | 2,145 | 737 | $37K | |
| 82784 | 3,923 | 2,956 | $37K | |
| 84146 | 2,825 | 2,405 | $37K | |
| 15271 | 61 | 24 | $37K | |
| 73620 | 1,074 | 912 | $36K | |
| D2930 | Prefabricated stainless steel crown - primary tooth | 677 | 73 | $36K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | 589 | 541 | $35K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 769 | 670 | $35K |
| 92134 | 5,386 | 4,887 | $34K | |
| 82378 | 4,044 | 3,586 | $34K | |
| 83520 | 2,108 | 1,628 | $33K | |
| 74178 | 258 | 234 | $33K | |
| 87070 | 5,026 | 4,296 | $32K | |
| 73110 | 790 | 697 | $32K | |
| G0260 | Injection procedure for sacroiliac joint; provision of anesthetic, steroid and/or other therapeutic agent, with or without arthrography | 415 | 310 | $32K |
| 97113 | 642 | 183 | $31K | |
| 11719 | 1,618 | 1,523 | $31K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | 1,280 | 1,167 | $31K |
| 81003 | 18,501 | 15,647 | $31K | |
| 96416 | 277 | 114 | $31K | |
| 82746 | 4,018 | 3,592 | $31K | |
| 93017 | 283 | 271 | $30K | |
| 97167 | 776 | 655 | $30K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 11,957 | 7,823 | $30K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | 76 | 73 | $29K |
| 83605 | 5,230 | 4,221 | $29K | |
| 70491 | 334 | 296 | $29K | |
| 72110 | 782 | 709 | $28K | |
| 83550 | 6,654 | 5,905 | $28K | |
| 83970 | 1,328 | 1,118 | $28K | |
| 87641 | 1,423 | 1,309 | $27K | |
| 86038 | 2,847 | 2,514 | $27K | |
| 83036 | Hemoglobin; glycosylated (A1C) | 4,334 | 3,690 | $26K |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 18,999 | 8,196 | $26K |
| 84439 | 3,484 | 2,915 | $26K | |
| 86703 | 2,299 | 2,045 | $25K | |
| 73600 | 677 | 584 | $24K | |
| 70498 | 312 | 279 | $24K | |
| 83540 | 7,120 | 6,309 | $24K | |
| 80076 | 6,988 | 6,234 | $23K | |
| 87400 | 1,071 | 949 | $22K | |
| 85379 | 3,385 | 2,993 | $22K | |
| 82803 | 1,735 | 1,481 | $22K | |
| 86225 | 3,060 | 2,728 | $21K | |
| 80177 | 2,391 | 2,001 | $21K | |
| 86235 | 562 | 410 | $20K | |
| 85610 | 9,020 | 7,171 | $20K | |
| 84153 | 1,518 | 1,391 | $20K | |
| 86803 | 2,321 | 2,088 | $20K | |
| 86300 | 2,538 | 2,242 | $20K | |
| 93970 | 239 | 219 | $20K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | 55 | 51 | $20K |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | 705 | 233 | $20K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 3,193 | 2,945 | $19K |
| 97166 | 396 | 367 | $19K | |
| 96411 | 566 | 322 | $19K | |
| 85730 | 5,966 | 5,106 | $19K | |
| 73552 | 632 | 538 | $19K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 21,817 | 18,307 | $19K |
| 86160 | 3,275 | 2,502 | $18K | |
| 92611 | 500 | 459 | $18K | |
| 97760 | 546 | 449 | $18K | |
| 83615 | 4,778 | 3,638 | $17K | |
| 71101 | 310 | 285 | $17K | |
| 82565 | 8,545 | 6,999 | $17K | |
| 82962 | 11,050 | 6,141 | $17K | |
| 76825 | 53 | 51 | $17K | |
| 72131 | 458 | 404 | $16K | |
| 82550 | 4,705 | 3,932 | $16K | |
| 82247 | 3,707 | 1,583 | $16K | |
| 85652 | 11,739 | 10,297 | $16K | |
| 78226 | 78 | 68 | $16K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 297 | 279 | $15K |
| 80074 | 491 | 439 | $15K | |
| J1720 | Injection, hydrocortisone sodium succinate, up to 100 mg | 2,915 | 2,117 | $15K |
| 87205 | 5,009 | 3,854 | $15K | |
| 11056 | 285 | 267 | $15K | |
| 19083 | 40 | 36 | $14K | |
| 88184 | 163 | 135 | $14K | |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | 680 | 636 | $14K |
| 87046 | 1,639 | 1,277 | $14K | |
| 29125 | 227 | 203 | $13K | |
| 84550 | 4,378 | 3,364 | $13K | |
| 93925 | 278 | 252 | $13K | |
| 94726 | 467 | 460 | $13K | |
| 87493 | 446 | 394 | $13K | |
| 86592 | 4,161 | 3,691 | $13K | |
| 64447 | 118 | 96 | $12K | |
| 92610 | 407 | 360 | $12K | |
| 82570 | 4,191 | 3,473 | $12K | |
| 73120 | 182 | 158 | $12K | |
| 87045 | 1,506 | 1,276 | $12K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 347 | 305 | $12K |
| J1459 | Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg | 15 | 12 | $12K |
| 80164 | 1,271 | 1,088 | $12K | |
| 73080 | 285 | 248 | $11K | |
| 31720 | 86 | 71 | $11K | |
| 11057 | 196 | 184 | $11K | |
| 84450 | 2,936 | 2,129 | $11K | |
| 64635 | 15 | 12 | $11K | |
| 93226 | 194 | 171 | $11K | |
| 77338 | 114 | 99 | $11K | |
| 64415 | 126 | 98 | $11K | |
| 86308 | 2,174 | 1,909 | $11K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | 161 | 138 | $10K |
| 86334 | 1,300 | 1,178 | $10K | |
| 90791 | Psychiatric diagnostic evaluation | 337 | 224 | $10K |
| 84165 | 2,366 | 2,141 | $10K | |
| 93225 | 182 | 159 | $9K | |
| 87075 | 1,632 | 1,360 | $9K | |
| 93975 | 62 | 57 | $9K | |
| 0240U | 1,833 | 1,711 | $9K | |
| 64450 | 82 | 72 | $9K | |
| 90686 | 2,059 | 1,882 | $9K | |
| 84156 | 3,821 | 2,958 | $9K | |
| J7030 | Infusion, normal saline solution , 1000 cc | 33,635 | 24,740 | $9K |
| 80047 | 883 | 844 | $9K | |
| 86704 | 1,386 | 1,222 | $9K | |
| D7140 | Extraction, erupted tooth or exposed root | 60 | 12 | $9K |
| 87340 | 1,577 | 1,392 | $8K | |
| 78306 | 60 | 55 | $8K | |
| 85014 | 4,859 | 3,856 | $8K | |
| 12002 | 100 | 83 | $8K | |
| 84132 | 2,873 | 2,457 | $8K | |
| 97163 | 137 | 125 | $8K | |
| 77290 | 44 | 38 | $8K | |
| 64615 | 203 | 181 | $8K | |
| 78264 | 43 | 41 | $7K | |
| 62321 | 44 | 39 | $7K | |
| 82948 | 2,111 | 1,606 | $7K | |
| 88312 | 386 | 231 | $7K | |
| 82140 | 1,032 | 837 | $7K | |
| 27096 | 95 | 91 | $7K | |
| G0008 | Administration of influenza virus vaccine | 2,329 | 2,129 | $7K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 11,925 | 9,245 | $7K |
| 85045 | 3,228 | 2,196 | $7K | |
| 90834 | Psychotherapy, 45 minutes with patient | 620 | 305 | $7K |
| 73060 | 202 | 170 | $7K | |
| 88112 | 375 | 325 | $6K | |
| 41899 | Unlisted procedure, dentoalveolar structures | 12 | 12 | $6K |
| 84238 | 398 | 362 | $6K | |
| 88185 | 484 | 147 | $6K | |
| 73140 | 154 | 125 | $6K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 18,392 | 12,532 | $6K |
| 86902 | 23 | 12 | $6K | |
| 86665 | 158 | 121 | $6K | |
| 73100 | 173 | 132 | $6K | |
| 82150 | 1,017 | 883 | $6K | |
| 93325 | 3,180 | 2,899 | $5K | |
| J9045 | Injection, carboplatin, 50 mg | 724 | 380 | $5K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 143 | 130 | $5K |
| 86769 | 182 | 171 | $5K | |
| 88360 | 113 | 65 | $5K | |
| 84100 | 1,416 | 1,194 | $5K | |
| 80069 | 1,351 | 923 | $5K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 41,447 | 31,192 | $5K |
| 76641 | 76 | 65 | $5K | |
| 93321 | 1,545 | 1,445 | $5K | |
| 86431 | 1,359 | 1,215 | $5K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 140 | 131 | $5K |
| 85576 | 248 | 213 | $5K | |
| 70360 | 97 | 85 | $4K | |
| 80143 | 635 | 522 | $4K | |
| 73221 | 57 | 54 | $4K | |
| 86200 | 627 | 554 | $4K | |
| 72050 | 114 | 109 | $4K | |
| 85018 | 2,523 | 2,161 | $4K | |
| 97542 | 169 | 124 | $4K | |
| 83883 | 659 | 380 | $4K | |
| 80179 | 620 | 519 | $4K | |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | 20 | 19 | $4K |
| 84481 | 274 | 254 | $4K | |
| 20553 | 47 | 42 | $4K | |
| 82272 | 1,563 | 1,359 | $4K | |
| 76827 | 53 | 51 | $3K | |
| J3489 | Injection, zoledronic acid, 1 mg | 174 | 156 | $3K |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | 2,615 | 2,327 | $3K |
| 86706 | 569 | 491 | $3K | |
| 85049 | 713 | 683 | $3K | |
| 96376 | 11,014 | 7,122 | $3K | |
| J1170 | Injection, hydromorphone, up to 4 mg | 14,029 | 9,614 | $3K |
| 93976 | 53 | 37 | $3K | |
| 86664 | 144 | 121 | $3K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 9,482 | 7,158 | $3K |
| 20552 | 48 | 42 | $3K | |
| 87210 | 754 | 651 | $3K | |
| 82010 | 488 | 400 | $3K | |
| 82274 | 186 | 180 | $3K | |
| 76870 | 41 | 36 | $3K | |
| 73070 | 64 | 55 | $3K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 4,836 | 3,733 | $3K |
| J1756 | Injection, iron sucrose, 1 mg | 853 | 351 | $3K |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 1,621 | 1,184 | $2K |
| 87899 | 274 | 237 | $2K | |
| 86430 | 451 | 386 | $2K | |
| 82310 | 1,559 | 1,295 | $2K | |
| 72197 | 25 | 24 | $2K | |
| 82465 | 695 | 643 | $2K | |
| 83721 | 320 | 295 | $2K | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 7,005 | 5,934 | $2K |
| 97535 | Self-care/home management training, each 15 minutes | 695 | 408 | $2K |
| 93990 | 99 | 98 | $2K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | 6,655 | 4,964 | $2K |
| 77280 | 42 | 36 | $2K | |
| 80050 | General health panel | 1,132 | 957 | $2K |
| 51702 | 65 | 64 | $2K | |
| 80185 | 181 | 148 | $2K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 34 | 28 | $2K |
| G0144 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system, under physician supervision | 57 | 56 | $2K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 1,192 | 948 | $2K |
| 99205 | Prolong outpt/office vis | 121 | 89 | $2K |
| 73521 | 53 | 51 | $2K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | 17,429 | 12,936 | $2K |
| 91010 | 15 | 12 | $2K | |
| 72158 | 12 | 12 | $2K | |
| J9190 | Injection, fluorouracil, 500 mg | 262 | 88 | $2K |
| 87177 | 180 | 159 | $2K | |
| 86696 | 112 | 101 | $2K | |
| 31624 | 15 | 15 | $2K | |
| 95816 | 12 | 12 | $2K | |
| 82947 | 604 | 535 | $2K | |
| 89050 | 660 | 544 | $2K | |
| 87116 | 394 | 340 | $1K | |
| 74174 | 19 | 12 | $1K | |
| 87102 | 413 | 364 | $1K | |
| J1815 | Injection, insulin, per 5 units | 4,284 | 1,714 | $1K |
| 90715 | 2,345 | 2,102 | $1K | |
| J9267 | Injection, paclitaxel, 1 mg | 293 | 121 | $1K |
| 84134 | 133 | 113 | $1K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 290 | 252 | $1K |
| 86039 | 175 | 162 | $1K | |
| 86695 | 113 | 102 | $1K | |
| 82800 | 184 | 150 | $1K | |
| A9270 | Non-covered item or service | 15,420 | 9,271 | $1K |
| J2997 | Injection, alteplase recombinant, 1 mg | 14 | 13 | $1K |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | 112 | 107 | $1K |
| 84460 | 251 | 239 | $1K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | 12 | 12 | $1K |
| 36589 | 13 | 12 | $1K | |
| 82043 | 576 | 519 | $1K | |
| 88173 | 82 | 69 | $1K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 16,184 | 13,755 | $1K |
| 84403 | 56 | 56 | $1K | |
| 96402 | 64 | 39 | $989.77 | |
| J2704 | Injection, propofol, 10 mg | 15,888 | 13,067 | $929.64 |
| 72128 | 32 | 28 | $895.16 | |
| 99152 | 9,641 | 8,487 | $884.52 | |
| 89055 | 276 | 241 | $877.58 | |
| 86880 | 83 | 80 | $872.45 | |
| 92650 | 40 | 37 | $869.04 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | 2,590 | 1,129 | $841.16 |
| 77470 | 13 | 13 | $832.18 | |
| 77002 | 947 | 819 | $808.50 | |
| 84155 | 1,184 | 1,072 | $781.65 | |
| L3030 | Foot, insert, removable, formed to patient foot, each | 73 | 43 | $755.90 |
| 87015 | 343 | 295 | $747.20 | |
| 86757 | 26 | 14 | $700.29 | |
| 64494 | 1,148 | 983 | $675.32 | |
| 88311 | 254 | 230 | $672.68 | |
| 97014 | 114 | 49 | $655.93 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 19,867 | 16,105 | $652.81 |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | 1,444 | 367 | $645.05 |
| Q3014 | Telehealth originating site facility fee | 113 | 109 | $638.06 |
| J0640 | Injection, leucovorin calcium, per 50 mg | 26 | 12 | $636.85 |
| 97032 | 140 | 61 | $605.18 | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 1,306 | 1,173 | $599.51 |
| 87503 | 35 | 29 | $577.12 | |
| A9537 | Technetium tc-99m mebrofenin, diagnostic, per study dose, up to 15 millicuries | 294 | 271 | $566.50 |
| 96101 | 39 | 30 | $561.38 | |
| J7050 | Infusion, normal saline solution, 250 cc | 9,524 | 4,173 | $542.93 |
| 76942 | 324 | 281 | $538.39 | |
| 76882 | 16 | 12 | $533.15 | |
| J1980 | Injection, hyoscyamine sulfate, up to 0.25 mg | 909 | 796 | $528.20 |
| 86376 | 33 | 30 | $523.69 | |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | 138 | 123 | $514.00 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 4,293 | 3,670 | $503.09 |
| 74220 | 12 | 12 | $463.60 | |
| 92004 | Ophthalmological services: medical examination and evaluation, comprehensive, new patient | 26 | 21 | $404.34 |
| 88321 | 28 | 25 | $403.17 | |
| 87206 | 252 | 222 | $397.98 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 6,755 | 5,672 | $363.14 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 799 | 518 | $358.32 |
| 82805 | 14 | 12 | $354.45 | |
| 99406 | 325 | 310 | $348.32 | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | 716 | 578 | $343.54 |
| C9399 | Unclassified drugs or biologicals | 162 | 137 | $338.72 |
| 82085 | 64 | 54 | $335.93 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | 3,657 | 3,121 | $328.30 |
| 82785 | 17 | 12 | $319.10 | |
| 83001 | 24 | 24 | $309.04 | |
| 86618 | 22 | 15 | $306.60 | |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | 1,989 | 1,703 | $300.75 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 1,319 | 1,093 | $288.16 |
| J0690 | Injection, cefazolin sodium, 500 mg | 10,700 | 8,128 | $272.88 |
| 82955 | 35 | 24 | $269.91 | |
| J3480 | Injection, potassium chloride, per 2 meq | 2,185 | 1,288 | $269.07 |
| 82670 | 14 | 14 | $257.95 | |
| 82040 | 50 | 46 | $244.11 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | 5,850 | 4,174 | $242.90 |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | 168 | 152 | $232.80 |
| J9263 | Injection, oxaliplatin, 0.5 mg | 23 | 12 | $227.64 |
| 97150 | Therapeutic procedure(s), group (2 or more individuals) | 392 | 261 | $219.22 |
| 88313 | 23 | 13 | $212.66 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 13,012 | 10,825 | $211.14 |
| 87209 | 14 | 12 | $195.57 | |
| 87420 | 19 | 13 | $187.96 | |
| 82077 | 46 | 40 | $186.65 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 9,158 | 7,705 | $181.50 |
| C1769 | Guide wire | 3,550 | 3,188 | $181.07 |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | 935 | 812 | $148.80 |
| 83010 | 58 | 57 | $148.51 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | 3,503 | 2,133 | $146.83 |
| 87329 | 13 | 12 | $146.52 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 860 | 670 | $144.65 |
| 94729 | 486 | 479 | $143.00 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | 2,608 | 2,120 | $138.00 |
| 88341 | 2,088 | 1,287 | $137.50 | |
| 90656 | 292 | 266 | $104.64 | |
| J2060 | Injection, lorazepam, 2 mg | 2,138 | 1,725 | $97.20 |
| 90732 | 18 | 18 | $85.04 | |
| 77012 | 242 | 222 | $74.16 | |
| 80178 | 12 | 12 | $73.40 | |
| 90670 | 13 | 13 | $66.57 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 2,169 | 1,859 | $64.35 |
| J0461 | Injection, atropine sulfate, 0.01 mg | 197 | 146 | $58.48 |
| 84145 | 3,444 | 2,996 | $54.42 | |
| 92201 | 389 | 334 | $53.53 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 2,128 | 1,652 | $52.36 |
| 82330 | 14 | 12 | $49.61 | |
| J1644 | Injection, heparin sodium, per 1000 units | 5,602 | 3,953 | $44.36 |
| 86593 | 15 | 13 | $41.56 | |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | 260 | 218 | $40.70 |
| 82525 | 15 | 14 | $39.25 | |
| 82365 | 14 | 13 | $34.83 | |
| 82668 | 12 | 12 | $33.82 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 218 | 171 | $26.40 |
| J1940 | Injection, furosemide, up to 20 mg | 2,441 | 1,765 | $23.07 |
| J3370 | Injection, vancomycin hcl, 500 mg | 2,544 | 1,474 | $21.71 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 615 | 568 | $18.02 |
| C9113 | Injection, pantoprazole sodium, per vial | 2,157 | 1,434 | $15.93 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 637 | 485 | $14.72 |
| J0736 | Injection, clindamycin phosphate, 300 mg | 204 | 167 | $12.12 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 2,468 | 1,890 | $10.45 |
| 91300 | 17 | 17 | $9.33 | |
| J2471 | Injection, pantoprazole (hikma), not therapeutically equivalent to j2470, 40 mg | 153 | 113 | $6.53 |
| 95874 | 39 | 37 | $5.89 | |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | 238 | 186 | $3.90 |
| 92202 | 77 | 73 | $3.62 | |
| J1956 | Injection, levofloxacin, 250 mg | 37 | 24 | $2.94 |
| 99153 | Mod sedat endo service >5yrs | 4,360 | 3,855 | $2.20 |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | 112 | 44 | $2.13 |
| 77063 | Screening digital breast tomosynthesis, bilateral | 1,239 | 1,123 | $1.52 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 388 | 305 | $1.02 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 300 | 276 | $0.66 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 135 | 111 | $0.66 |
| 36592 | 22 | 17 | $0.13 | |
| J1920 | Injection, labetalol hydrochloride, 5 mg | 33 | 25 | $0.07 |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | 701 | 416 | $0.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 5,042 | 4,481 | $0.00 |
| J1953 | Injection, levetiracetam, 10 mg | 563 | 356 | $0.00 |
| C1788 | Port, indwelling (implantable) | 70 | 61 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 235 | 216 | $0.00 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 1,436 | 1,242 | $0.00 |
| C1760 | Closure device, vascular (implantable/insertable) | 1,241 | 1,106 | $0.00 |
| 77387 | 1,103 | 105 | $0.00 | |
| C9257 | Injection, bevacizumab, 0.25 mg | 901 | 811 | $0.00 |
| 97598 | 139 | 78 | $0.00 | |
| 84112 | 934 | 790 | $0.00 | |
| Q4186 | Epifix, per square centimeter (add-on, list separately in addition to primary procedure) | 712 | 275 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 727 | 653 | $0.00 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 1,056 | 887 | $0.00 |
| G8997 | Swallowing functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 201 | 185 | $0.00 |
| C1776 | Joint device (implantable) | 99 | 84 | $0.00 |
| C1874 | Stent, coated/covered, with delivery system | 94 | 82 | $0.00 |
| G8996 | Swallowing functional limitation, current status at therapy episode outset and at reporting intervals | 178 | 163 | $0.00 |
| J7510 | Prednisolone oral, per 5 mg | 90 | 87 | $0.00 |
| 93356 | 52 | 48 | $0.00 | |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | 332 | 302 | $0.00 |
| 76937 | 71 | 65 | $0.00 | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | 63 | 61 | $0.00 |
| A9541 | Technetium tc-99m sulfur colloid, diagnostic, per study dose, up to 20 millicuries | 43 | 41 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 363 | 268 | $0.00 |
| 0042T | 13 | 12 | $0.00 | |
| J3260 | Injection, tobramycin sulfate, up to 80 mg | 72 | 64 | $0.00 |
| 64636 | 15 | 12 | $0.00 | |
| 84166 | 25 | 24 | $0.00 | |
| 77085 | 33 | 27 | $0.00 | |
| J1020 | Injection, methylprednisolone acetate, 20 mg | 16 | 16 | $0.00 |
| Q0245 | Injection, bamlanivimab and etesevimab, 2100 mg | 17 | 17 | $0.00 |
| J2305 | Injection, nitroglycerin, 5 mg | 72 | 67 | $0.00 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 1,363 | 1,123 | $0.00 |
| 36416 | 4,001 | 1,911 | $0.00 | |
| J1630 | Injection, haloperidol, up to 5 mg | 307 | 260 | $0.00 |
| A4648 | Tissue marker, implantable, any type, each | 180 | 159 | $0.00 |
| 96368 | 574 | 361 | $0.00 | |
| 77001 | 557 | 483 | $0.00 | |
| 93320 | 338 | 318 | $0.00 | |
| 94760 | 986 | 723 | $0.00 | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | 1,449 | 1,347 | $0.00 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 429 | 179 | $0.00 |
| 11045 | 199 | 113 | $0.00 | |
| 99243 | 1,432 | 1,255 | $0.00 | |
| J7999 | Compounded drug, not otherwise classified | 3,243 | 2,498 | $0.00 |
| G0009 | Administration of pneumococcal vaccine | 200 | 199 | $0.00 |
| A9561 | Technetium tc-99m oxidronate, diagnostic, per study dose, up to 30 millicuries | 41 | 40 | $0.00 |
| C1889 | Implantable/insertable device, not otherwise classified | 860 | 699 | $0.00 |
| J1741 | Injection, ibuprofen, 100 mg | 448 | 263 | $0.00 |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 173 | 163 | $0.00 |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | 144 | 138 | $0.00 |
| A9503 | Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries | 94 | 86 | $0.00 |
| 77417 | 276 | 120 | $0.00 | |
| C2623 | Catheter, transluminal angioplasty, drug-coated, non-laser | 71 | 71 | $0.00 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | 190 | 176 | $0.00 |
| C2617 | Stent, non-coronary, temporary, without delivery system | 204 | 168 | $0.00 |
| 94660 | 68 | 39 | $0.00 | |
| 80320 | 513 | 430 | $0.00 | |
| 80329 | 193 | 145 | $0.00 | |
| G8982 | Changing & maintaining body position functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 15 | 14 | $0.00 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | 243 | 142 | $0.00 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 147 | 84 | $0.00 |
| J2785 | Injection, regadenoson, 0.1 mg | 51 | 49 | $0.00 |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 90 | 89 | $0.00 |
| G8998 | Swallowing functional limitation, discharge status, at discharge from therapy or to end reporting | 44 | 42 | $0.00 |
| J3490 | Unclassified drugs | 52 | 43 | $0.00 |
| J0456 | Injection, azithromycin, 500 mg | 22 | 12 | $0.00 |
| J3410 | Injection, hydroxyzine hcl, up to 25 mg | 16 | 16 | $0.00 |
| J3360 | Injection, diazepam, up to 5 mg | 31 | 26 | $0.00 |